A case of lichenoid oral mucositis associated with nivolumab therapy
- 1 January 2022
- journal article
- research article
- Published by Wiley in Oral Science International
- Vol. 19 (1) , 68-71
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 TherapyClinical Cancer Research, 2016
- Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohortJournal of the American Academy of Dermatology, 2016
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialThe Lancet Oncology, 2015
- Toxicity Patterns With Immunomodulating Antibodies and Their CombinationsSeminars in Oncology, 2015
- Managing Immune Checkpoint-Blocking Antibody Side EffectsAmerican Society of Clinical Oncology Educational Book, 2015
- The future of immune checkpoint therapyScience, 2015
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Increased B7-H1 Expression on Peripheral Blood T Cells in Oral Lichen Planus Correlated with Disease SeverityJournal of Clinical Immunology, 2012